[go: up one dir, main page]

NO20030989D0 - 4-Halogenated 17-Methylene Steroids, Process for Preparation thereof and Pharmaceutical Preparations Containing These Compounds - Google Patents

4-Halogenated 17-Methylene Steroids, Process for Preparation thereof and Pharmaceutical Preparations Containing These Compounds

Info

Publication number
NO20030989D0
NO20030989D0 NO20030989A NO20030989A NO20030989D0 NO 20030989 D0 NO20030989 D0 NO 20030989D0 NO 20030989 A NO20030989 A NO 20030989A NO 20030989 A NO20030989 A NO 20030989A NO 20030989 D0 NO20030989 D0 NO 20030989D0
Authority
NO
Norway
Prior art keywords
compounds
halogenated
preparation
pharmaceutical preparations
preparations containing
Prior art date
Application number
NO20030989A
Other languages
Norwegian (no)
Other versions
NO20030989L (en
NO325012B1 (en
Inventor
Bernd Menzenbach
Walter Elger
Peter Droescher
Alexander Hillisch
Guenter Kaufmann
Hans-Udo Schweikert
Gerd Mueller
Original Assignee
Jenapharm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jenapharm Gmbh filed Critical Jenapharm Gmbh
Publication of NO20030989D0 publication Critical patent/NO20030989D0/en
Publication of NO20030989L publication Critical patent/NO20030989L/en
Publication of NO325012B1 publication Critical patent/NO325012B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to 17-Methylene steroids. Method for the production thereof and pharmaceutical compositions containing these compounds. The inventive compounds have an active profile with a hybrid character of such that they act as inhibitors of the 5 alpha -reductase and, at the same time, as gestagens. Said compounds are thus suited for treating medical disorders that, in men and women, are a result of an increased androgen level in certain organs and tissues. The inventive compounds combined with other hormonal substances such as estrogen, testosterone or a potent androgen are suited as contraceptives for women and men.
NO20030989A 2000-09-04 2003-03-03 4-halogenated 17-methylene steroids, processes for their preparation and pharmaceutical compositions containing these compounds, and use of the compounds for the manufacture of medicaments NO325012B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10043846A DE10043846A1 (en) 2000-09-04 2000-09-04 17-methylene steroids, process for their preparation and pharmaceutical compositions containing them
PCT/EP2001/009943 WO2002019971A1 (en) 2000-09-04 2001-08-29 4-halogenated 17-methylene steroids, method for the production thereof and pharmaceutical compositions containing these compounds

Publications (3)

Publication Number Publication Date
NO20030989D0 true NO20030989D0 (en) 2003-03-03
NO20030989L NO20030989L (en) 2003-05-02
NO325012B1 NO325012B1 (en) 2008-01-14

Family

ID=7655148

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20030989A NO325012B1 (en) 2000-09-04 2003-03-03 4-halogenated 17-methylene steroids, processes for their preparation and pharmaceutical compositions containing these compounds, and use of the compounds for the manufacture of medicaments

Country Status (28)

Country Link
EP (1) EP1423407B1 (en)
JP (1) JP2004513084A (en)
KR (1) KR100530816B1 (en)
CN (1) CN1262560C (en)
AT (1) ATE319733T1 (en)
AU (2) AU2002210470B2 (en)
BG (1) BG107594A (en)
BR (1) BR0113618A (en)
CA (1) CA2421302C (en)
DE (2) DE10043846A1 (en)
DK (1) DK1423407T3 (en)
EA (1) EA006387B1 (en)
EE (1) EE05186B1 (en)
ES (1) ES2260294T3 (en)
HR (1) HRP20030256A2 (en)
HU (1) HUP0300936A3 (en)
IL (2) IL154666A0 (en)
ME (1) MEP14408A (en)
MX (1) MXPA03001912A (en)
NO (1) NO325012B1 (en)
NZ (1) NZ524485A (en)
PL (1) PL360669A1 (en)
PT (1) PT1423407E (en)
RS (1) RS50305B (en)
SK (1) SK286757B6 (en)
UA (1) UA74592C2 (en)
WO (1) WO2002019971A1 (en)
ZA (1) ZA200301715B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10141984A1 (en) 2001-08-28 2003-03-20 Jenapharm Gmbh New 17-methylene-4-azasteroids
US7199115B2 (en) 2004-04-19 2007-04-03 Schering Ag 17α-fluorosteroids, pharmaceutical compositions containing 17α-fluorosteroids and a method of making them
AT12800U1 (en) * 2007-11-05 2012-11-15 Bayer Schering Pharma Ag A pharmaceutical preparation for use in the oral contraception of lactose intolerant women

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2611773A (en) * 1951-08-21 1952-09-23 Upjohn Co Estradiol 17-cyclopenetanepropionate
US3146239A (en) * 1957-09-23 1964-08-25 Syntex Corp 4-halo-19-nor-progesterone
US3232960A (en) * 1959-10-08 1966-02-01 Upjohn Co 3-keto-4-fluoro- and 3-keto-4,4-difluorosteroids and process
US3661940A (en) * 1970-04-13 1972-05-09 Sandoz Ag Derivatives of 21-methyl-19-norpregnanes
US4389345A (en) * 1981-10-09 1983-06-21 G.D. Searle & Co. 3-Oxoestra-17-acetonitrile and unsaturated analogs
US5994334A (en) * 1997-02-05 1999-11-30 University Of Maryland Androgen synthesis inhibitors
WO2002000681A1 (en) * 2000-06-27 2002-01-03 Aventis Pharma S.A. 20-fluoro-17(20)-vinyl steroids as inhibitors of c17-20-lyase and 5-alpha reductase

Also Published As

Publication number Publication date
IL154666A0 (en) 2003-09-17
PL360669A1 (en) 2004-09-20
BR0113618A (en) 2003-07-15
EP1423407B1 (en) 2006-03-08
EP1423407A1 (en) 2004-06-02
EE05186B1 (en) 2009-06-15
NZ524485A (en) 2005-11-25
WO2002019971A9 (en) 2002-08-08
HUP0300936A2 (en) 2003-11-28
EE200300087A (en) 2005-02-15
YU16403A (en) 2006-05-25
MXPA03001912A (en) 2004-07-08
PT1423407E (en) 2006-07-31
HUP0300936A3 (en) 2010-01-28
CN1452628A (en) 2003-10-29
CN1262560C (en) 2006-07-05
SK2442003A3 (en) 2003-08-05
AU2002210470B2 (en) 2006-07-20
CA2421302A1 (en) 2003-03-03
CA2421302C (en) 2007-08-14
ATE319733T1 (en) 2006-03-15
SK286757B6 (en) 2009-05-07
JP2004513084A (en) 2004-04-30
RS50305B (en) 2009-09-08
WO2002019971A1 (en) 2002-03-14
IL154666A (en) 2008-12-29
UA74592C2 (en) 2006-01-16
DK1423407T3 (en) 2006-07-03
NO20030989L (en) 2003-05-02
DE10043846A1 (en) 2002-04-04
EA200300322A1 (en) 2003-10-30
ZA200301715B (en) 2004-08-13
NO325012B1 (en) 2008-01-14
DE50109175D1 (en) 2006-05-04
HK1060135A1 (en) 2004-07-30
HRP20030256A2 (en) 2005-10-31
ES2260294T3 (en) 2006-11-01
KR20030028836A (en) 2003-04-10
AU1047002A (en) 2002-03-22
MEP14408A (en) 2010-06-10
KR100530816B1 (en) 2005-11-25
EA006387B1 (en) 2005-12-29
BG107594A (en) 2003-09-30

Similar Documents

Publication Publication Date Title
MA26843A1 (en) NOVEL TOPICAL ESTRO-PROGESTIVE COMPOSITIONS WITH SYSTEMIC EFFECT
UA66861C2 (en) 2-phenyl-1-[4-(2-aminoeihoxy)benzyl]-indole in combination with estrogens, method for treatment and pharmaceutical product
NO20012774D0 (en) Preparation and method using essential plant oils
DE60141587D1 (en) PROCESS FOR TREATING EFFECTS AND INCREASING LIBIDO IN MEN
WO2002040702A3 (en) Methods for the treatment of cancer and other diseases and methods of developing the same
DE60115274D1 (en) USE OF ANTIPROGESTINES FOR PROPHYLAXIS AND TREATMENT OF HORMONE-RELATED DISEASES
WO2002019982A3 (en) Cosmetic composition and method for reducing or preventing wrinkling
ATE279208T1 (en) METHOD AND SUBSTANCES FOR THE TREATMENT OF PROSTATE CARCINOMA
JP2004508317A5 (en)
WO2006023496A3 (en) Vaginal cream compositions, kits thereof and methods of using thereof
BR0008437A (en) Steroid sulfatase inhibitors and methods for their manufacture and use
EA200100674A1 (en) CLEDRATES DEHYDROEPIANDROSTERONE AND RELATED PHARMACEUTICAL COMPOSITIONS
NO20030989L (en) 4-Halogenated 17-Methylene Steroids, Process for Preparation thereof and Pharmaceutical Preparations Containing These Compounds
NO984075D0 (en) Combination of dehydroepiandrosterone and aromatase inhibitors and use of this combination for the manufacture of a medicament for the treatment of a relative and absolute androgen deficiency in men
BG103060A (en) 19- NOR- HOLAN STEROIDS AS THE NEUROCHEMICAL INITIATORS OF CHANGE IN THE ACTION OF HYPOTHALAMUS IN HUMAN
MXPA05008347A (en) Compositon comprising a combination of an aromatase inhibitor, a progestin and an oestrogen and its use for the treatment of endometriosis.
UA85190C2 (en) PROCESS FOR THE SYNTHESIS OF PURE D-(17α)-13-ETHYL-17-HYDROXY-18,19-DINORPREGN-4-ENE-20-YNE-3-ONE-3E- AND -3Z-OXIME ISOMERS AND THE MIXTURE OF ISOMERS, AND USE OF THOSE ISOMERS
JPH0733673A (en) Testosterone-5α-reductase inhibitor
DE59907558D1 (en) AGENTS FOR STABILIZING FOOD AND COSMETIC AGENTS AND METHOD FOR THE PRODUCTION THEREOF
WO2003045971A3 (en) Solvates of 3.beta., 28-diacetoxy-18-oxo-19, 20, 21, 29, 30-pentanorlupan-22-oic acid, processes for their preparation and pharmaceutical compositions thereof
AR048829A1 (en) 17ALFA - FLUOROSTEROIDS WITH INHIBITING ACTIVITY OF 5 ALFA-REDUCTASA; PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE IN THE PREPARATION OF MEDICINES FOR THE TREATMENT OF CANCER DISEASES INFLUENCED BY ANDROGENS.
AR032371A1 (en) USE OF ANTIPROGESTINES FOR PROFILAXIS AND TREATMENT OF HORMONE DEPENDENT DISEASES
BR0016092A (en) Compound, use of a compound kit for hormonal contraception in a male, and method of treatment
NO20022713L (en) 14,15-cyclopropane steroids from the 19-norandrostancer series, process for the preparation of the compounds, and pharmaceutical preparations containing the compounds

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees